Clinical Context
The GLP-1 receptor agonist class has expanded substantially, giving clinicians multiple options with different pharmacokinetic profiles, dosing frequencies, and efficacy/tolerability characteristics. Head-to-head comparisons between GLP-1 RAs help inform treatment selection, particularly when patients fail to achieve adequate response or experience intolerable side effects with one agent.
Exenatide extended-release (ER) was the first once-weekly GLP-1 RA, providing proof-of-concept that weekly dosing could maintain continuous GLP-1 receptor activation. Semaglutide, a later-generation once-weekly agent, was specifically designed for enhanced albumin binding and prolonged half-life. The SUSTAIN 3 trial directly compared these two once-weekly options to determine whether newer necessarily means better.
For patients already on oral antidiabetic therapy requiring intensification, the choice between once-weekly GLP-1 RAs has practical implications. Understanding the magnitude of efficacy differences helps clinicians and patients decide whether to start with one agent over another, or whether to switch agents if initial response is insufficient.
PICO Summary
Population: Adults with type 2 diabetes (n=813) on stable oral antidiabetic medications (metformin, sulfonylureas, or thiazolidinediones).
Intervention: Once-weekly subcutaneous semaglutide 1.0 mg for 56 weeks.
Comparison: Once-weekly exenatide extended-release 2.0 mg for 56 weeks.
Outcome: Semaglutide reduced HbA1c by 1.5% versus 0.9% with exenatide ER. Weight loss was 5.6 kg with semaglutide compared to 1.9 kg with exenatide ER. More patients achieved HbA1c <7.0% with semaglutide (67% vs 40%). Gastrointestinal adverse events were more frequent with semaglutide (41.8% vs 33.3%), while exenatide ER caused more injection-site reactions (22.0% vs 1.2%).
Clinical Pearls
1. Semaglutide Demonstrates Clear Superiority Within Class: The 0.6% additional HbA1c reduction and nearly 4 kg greater weight loss with semaglutide represent clinically meaningful differences between two agents in the same class. Not all GLP-1 RAs are equivalent—semaglutide offers substantially greater efficacy than exenatide ER.
2. Target Achievement Rates Favor Semaglutide: The 67% vs 40% achievement of HbA1c <7.0% translates to meaningfully more patients reaching glycemic goals. This difference affects long-term complication risk and may reduce need for additional therapy escalation.
3. Different Side Effect Profiles: Semaglutide causes more GI side effects (nausea, vomiting, diarrhea), while exenatide ER causes more injection-site reactions (nodules from the microsphere formulation). For patients who cannot tolerate GI effects, exenatide ER remains an option. For patients bothered by injection-site nodules, semaglutide’s clear formulation may be preferred.
4. 56-Week Duration Confirms Sustained Benefits: The efficacy differences persisted throughout the full 56-week trial period, confirming that semaglutide’s advantages are durable rather than transient initial effects.
Practical Application
When initiating once-weekly GLP-1 RA therapy, semaglutide should generally be preferred over exenatide ER based on superior efficacy for both glycemic control and weight loss. The magnitude of differences (0.6% HbA1c, 3.7 kg weight) are clinically meaningful and justify starting with the more effective agent.
Consider exenatide ER when: semaglutide causes intolerable GI side effects despite slow titration, cost/formulary restrictions favor exenatide ER, or patients specifically prefer the exenatide ER pen device. Some patients who fail semaglutide due to GI intolerance may tolerate exenatide ER better.
The open-label design means patients knew which drug they received—this may have influenced adherence and reporting of side effects but is unlikely to explain the objective glycemic differences. When counseling patients about GI side effects, note that these typically improve over weeks to months and can be minimized with gradual dose titration.
Broader Evidence Context
SUSTAIN 3 is part of the comprehensive SUSTAIN program that established semaglutide’s efficacy across the T2D treatment spectrum. Similar superiority over other comparators was demonstrated throughout the program: sitagliptin (SUSTAIN 2), insulin glargine (SUSTAIN 4), and placebo (SUSTAIN 1). The consistency of semaglutide’s performance across trials supports its positioning as a highly effective GLP-1 RA option.
Subsequent cardiovascular outcome trials (SUSTAIN-6, SELECT) demonstrated that semaglutide reduces cardiovascular events, adding another consideration favoring this agent for patients with cardiovascular disease or risk factors.
Study Limitations
The open-label design means patients and investigators knew treatment assignments, potentially influencing subjective outcomes and discontinuation decisions. Exenatide ER’s maximum dose (2.0 mg) may not represent its full potential, though this is the approved maximum. The trial did not assess cardiovascular or other long-term outcomes.
Bottom Line
Once-weekly semaglutide 1.0 mg provides substantially greater glycemic control and weight loss compared to once-weekly exenatide ER 2.0 mg in patients with type 2 diabetes on oral therapy. This head-to-head superiority supports semaglutide as the preferred once-weekly GLP-1 RA for most patients.
Source: Ahmann AJ, et al. “Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.” Diabetes Care, 2018;41(2):258-266. Read article
